GALECTIN THERAPEUTICS INC

Insider buying at Galectin Therapeutics shows long‑term confidence in its fibrotic and cancer drug pipeline, even amid volatile social‑media buzz.

Galectin Therapeutics insider buys low, sells high—Jamil Khurram’s 10b5‑1 plan signals confidence in the company’s fibrotic & cancer pipeline and upcoming clinical milestones.

Insider buying by Galectin Therapeutics’ CMO signals confidence in belapectin and a potential upside, sparking investor interest and a modest weekly gain.

CEO Lewis Joel sells 56k Galectin Therapeutics shares—what the move means for insider confidence, liquidity, and the company’s future.